- Home
- KRYS vs AXSM Comparison
KRYS vs AXSM Comparison
Compare KRYS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRYS
- AXSM
- Stock Information
- Founded
- KRYS 2015
- AXSM 2012
- Country
- KRYS United States
- AXSM United States
- Employees
- KRYS N/A
- AXSM N/A
- Industry
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- KRYS Health Care
- AXSM Health Care
- Exchange
- KRYS Nasdaq
- AXSM Nasdaq
- Market Cap
- KRYS 4.3B
- AXSM 5.1B
- IPO Year
- KRYS 2017
- AXSM 2015
- Fundamental
- Price
- KRYS $144.86
- AXSM $122.85
- Analyst Decision
- KRYS Strong Buy
- AXSM Strong Buy
- Analyst Count
- KRYS 10
- AXSM 17
- Target Price
- KRYS $204.90
- AXSM $175.76
- AVG Volume (30 Days)
- KRYS 268.2K
- AXSM 560.9K
- Earning Date
- KRYS 11-03-2025
- AXSM 11-11-2025
- Dividend Yield
- KRYS N/A
- AXSM N/A
- EPS Growth
- KRYS 36.22
- AXSM N/A
- EPS
- KRYS 4.91
- AXSM N/A
- Revenue
- KRYS $359,205,000.00
- AXSM $495,033,000.00
- Revenue This Year
- KRYS $34.33
- AXSM $64.05
- Revenue Next Year
- KRYS $47.84
- AXSM $56.46
- P/E Ratio
- KRYS $29.46
- AXSM N/A
- Revenue Growth
- KRYS 116.08
- AXSM 69.83
- 52 Week Low
- KRYS $122.80
- AXSM $75.56
- 52 Week High
- KRYS $207.84
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- KRYS 48.61
- AXSM 60.12
- Support Level
- KRYS $136.73
- AXSM $122.03
- Resistance Level
- KRYS $152.96
- AXSM $130.00
- Average True Range (ATR)
- KRYS 4.68
- AXSM 3.40
- MACD
- KRYS -0.69
- AXSM -0.21
- Stochastic Oscillator
- KRYS 50.09
- AXSM 48.97
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.